wto姐妹会

Pfizer cuts full-year outlook due to declining sales of Covid-19-related products_我的网站

一 | 1月16日，据外媒报道，索尼已于2019年向俄罗斯和意大利媒体发出了有关MWC的邀请函，确认将于2月25日举行新闻发布会，届时将发布长时间曝光的“鱼屏”新飞机。

二 |     Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。有传言称，索尼将在MWC 2019上发布其下一个旗舰产品Xperia XZ4（目前还不确定其名称），首次推出6.5英寸21:9大屏幕，以及一个玻璃镜和一个后部的三相机器。在配置方面，新飞机将配备高通555、256 GB存储、3900 mAh电池和Android 9 Pie系统。此外，索尼预计将推出Xperia L3、Xperia Xa3和Xperia Xa3 Ultra，这将是索尼最新的入门级和中端产品。

Current article:http://z8v34u.suiyangguiduanzudoushaopao.buzz/news/20260826_103.html

Published on:07:07:21